By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agilis Biotherapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Agilis Biotherapeutics Announces Orphan Designation Approval In Europe For The Treatment Of AADC Deficiency 12/1/2016 8:16:23 AM
Agilis Biotherapeutics Achieves FDA "Rare Pediatric Disease" Designation For AADC Gene Therapy Candidate 11/17/2016 11:24:08 AM
Agilis Biotherapeutics Announces First Patient Treated In Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency 11/16/2016 11:35:30 AM
Agilis Biotherapeutics Announces Authorization Of Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency 10/11/2016 8:48:07 AM
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Friedreich’s Ataxia (FA) 8/2/2016 8:55:35 AM
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Aromatic L-Amino Acid Decarboxylase Deficiency 6/29/2016 9:29:01 AM
Agilis Biotherapeutics, First Gene Therapy Company Selected For NIH Therapeutics For Rare And Neglected Diseases Program 6/27/2016 10:03:39 AM
Agilis Biotherapeutics Release: Newborn Screening Study For AADC Deficiency Published In Molecular Genetics And Metabolism 6/2/2016 11:37:55 AM
Agilis Biotherapeutics Announces Orphan Designation Approval In Europe For The Treatment Of Angelman Syndrome 5/4/2016 10:55:57 AM
Agilis Biotherapeutics And T-Top Clinical Research Co. Ltd. Enter Into An Agreement For The Development Of Gene Therapy Treatment Of AADC Deficiency 3/22/2016 10:50:55 AM
123
//-->